Fagundo-Sierra R, Sánchez-Saínz A, Pérez-Jáuregui J

Language: Spanish
References: 22
Page: 124-131
PDF size: 118.91 Kb.

ABSTRACT

The aim of this study was to assess the resistance to antibiotics of 1,751 strains of genital mycoplasms and ureaplasms from clinical samples of Mexican patients and to identify changes in their resistance pattern, since January 2001 to November 2005. The culture and the sensitivity tests were done using the method described in the Mycoplasma IST2 kit (bioMérieux, France), and validated using the ATCC No. 27813 reference strain. For the antibiogram, nine antibiotics described to be effective against this group of microorganisms were used: four macrolides: azithromycin, erythromycin, clarithromycin and josamycin; two fluoroquinolones: ciprofloxacin and ofloxacin; two tetracyclines: doxicyclin and tetracycline, and a streptogramine: pristinamycin. Of the 81 (5%) samples, Mycoplasma hominis was isolated, in 1,535 (88%) Ureaplasma urealyticum was isolated, and in 135 (8%) both microorganisms (M. hominis + U. urealyticum) were found. The antibiotics to which the organisms were more sensitive to were josamycin, pristinamycin, doxycycline and tetracycline. M. hominis showed greater resistance to azithromycin, erythromycin, clarithromycin and ciprofloxacin, while U. urealyticum was resistant to ciprofloxacin and ofloxacin. In mixed isolates, there was an increased resistance to all the antibiotics assessed. During the period studied, an increased annual resistance (p ‹ 0.05) of M. hominis to ofloxacin, and U. urealyticum (p ‹ 0.05) to ofloxacin, erythromycin, josamycin and doxycycline was seen, as well as an increase in the isolates resistant to all antibiotics.

REFERENCES

1. Rivera JA, Cedillo ML, Vega M. Micoplasmas y su importancia médica. Rev Biomed 2001; 12: 262-271.

2. Kataoka S, Yamada T, Chou K, Nishida R, Morikawa M, Minami M, et al. Association between preterm birth and vaginal colonization by mycoplasmas in early pregnancy. J Clin Microbiol 2006; 44: 51-55.

3. Wang Y, Liang CL, Wu JQ, Xu C, Qin SX, Gao ES. Do Ureaplasma urealyticum infections in the genital tract affect semen quality? Asian J Androl 2006; 8: 562-568.

4. Howard BJ. Clinical and pathogenic microbiology. 2nd. St. Louis, MO: Mosby-Year Book; 1994: 491-502.

5. Taylor D, Bebear C. Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections. J Antimicrob Chemother 1997; 40: 622-630.

6. Bébéar C, Renaudin H, Charrion A, Clerc M, Pereyre S, Bebear C. DNA girasa and topoisomerasa IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolonas. Antimicrob Agents Chemother 2003; 47: 3323-3325.

7. Guo X, Ye Z, Deng R. Male urogenital tract mycoplasma infection and drug resistance evolution. Zhonghua Nan Ke Xue 2004; 10: 122-124.

8. Bébéar C, Barbeyrac B, Dewilde A, Edert D, Janvresse C, Layani M, et al. Multicenter study of the in vitro sensitivity of genital mycoplasmas to antibiotics. Pathol Biol (Paris) 1993; 441: 289-293.

9. Kilic D, Basar MM, Kaygusuz S, Yilmaz E, Basar H, Batislam E. Prevalence and treatment of Chlamydia trachomatis, Ureaplasma urealyticum, and Mycoplasma hominis in patients with non-gonococcal urethritis. Jpn J Infect Dis 2004; 57: 17-20.

10. Ullmann U, Shubert S, Krausse R. Comparative in-vitro activity of levofloxacina, other fluoroquinolones, doxicycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis. J Antimicrob Chemother 1999; A(3): 33-36.

11. Bauriaud R, Seror C, Lareng MB, Lefevre JC. In vitro sensitivity to antibiotics of genital mycoplasmas isolated in Toulouse. Study of new molecules (macrolides and quinolones). Pathol Biol (Paris) 1992; 40: 479-482.

12. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL. Harrison, principios de medicina interna. 15a ed. México: Mc Graw-Hill Interamericana; 2002: 1267.

13. Ramírez C, Casanova G, Menocal G, Ortiz J, Ahued R. Prevalencia de la infección cervicovaginal por Mycoplasma hominis y Ureaplasma urealyticum en pacientes ginecológicas del Instituto Nacional de Perinatología. Enf Infec Microbiol 2004; 24: 1-5.

14. Narcio ML, Solórzano F, Arredondo JL, Calderon E, Beltran M. Etiology of cervicovaginal infection in pregnant and non-pregnant patients. Ginecol Obstet Mex 1989; 57: 41-46.

15. Rivera JA, Centeno M, Santillán M, Rodríguez N. Prevalencia de Ureaplasma urealyticum en mujeres. Rev Mex Patol Clin 2004; 51: 33-36.

16. Zuo CX, Huang JH, Chen J, Lu JY, Xiang YP. Female urogenital mycoplasma infection and drug sensitivity status in Changsha. Nan Fang Yi Ke Da Xue Xue Bao 2006; 26: 831-836.

17. Karabay O, Topcuoglu A, Kocoglu E, Gurel S, Gurel H, Ince NK. Prevalence and antibiotic susceptibility of genital Mycoplasma hominis and Ureaplasma urealyticum in a university hospital in Turkey. Clin Exp Obstet Gynecol 2006; 33: 36-38.

18. Pereyre S, Gonzalez P, de Barbeyrac B, Darnige A, Renaudin H, Charron A, et al. Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis. Antimicrob Agents Chemother 2002; 46: 3142-3150.

19. Huang C, Liu Z, Lin N, Tu Y, Li J, Zhang D. Susceptibility of mixed infection of Ureplasma urealyticum and Mycoplasma hominis to seven antimicrobial agents and comparison with that of Ureaplasma urealyticum infection. J Huazhong Univ Sci Technolog Med Sci 2003; 23: 203-205.

20. Giner S, Canós C, Rodilla C, Ferrer G. Nuevos macrólidos ¿superan a eritromicina? Farm Hosp 1995; 19: 259-265.

21. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. Morbidity Mortality Weekly. Report, 2002 Vol. 51 (No.RR-6), 30-42.

22. Xie X, Zhang J. Trends in the rates of resistance of Ureaplasma urealyticum to antibiotics and identification of the mutation site in the quinolone resistance-determining region in Chinese patients. FEMS Microbiol Lett 2006; 259: 181-186.